Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study

The combination of paclitaxel and ramucirumab is the second-line therapy of choice in the treatment of advanced gastric cancer. To date, no biomarkers are available in gastric cancer to predict the outcome of antiangiogenic therapy. The present prospective study included 35 patients undergoing secon...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessandro, Rosalba, Refolo, Maria Grazia, Schirizzi, Annalisa, De Leonardis, Giampiero, Donghia, Rossella, Guerra, Vito, Giannelli, Gianluigi, Lolli, Ivan Roberto, Laterza, Maria Maddalena, De Vita, Ferdinando, Messa, Caterina, Lotesoriere, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019360/
https://www.ncbi.nlm.nih.gov/pubmed/35463372
http://dx.doi.org/10.3389/fonc.2022.862116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019360/
https://www.ncbi.nlm.nih.gov/pubmed/35463372
http://dx.doi.org/10.3389/fonc.2022.862116

Ejemplares similares